Your browser doesn't support javascript.
loading
Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia
Silva, Rita Santos; Carvalho, Berta; Pedro, Jorge; Castro-Correia, Cíntia; Carvalho, Davide; Carvalho, Filipa; Fontoura, Manuel.
  • Silva, Rita Santos; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
  • Carvalho, Berta; Universidade do Porto. Faculdade de Medicina. Departamento de Patologia. PT
  • Pedro, Jorge; Universidade do Porto. Instituto de Investigação e Inovação em Saúde. Faculdade de Medicina. PT
  • Castro-Correia, Cíntia; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
  • Carvalho, Davide; Universidade do Porto. Instituto de Investigação e Inovação em Saúde. Faculdade de Medicina. PT
  • Carvalho, Filipa; Universidade do Porto. Faculdade de Medicina. Departamento de Patologia. PT
  • Fontoura, Manuel; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
Arch. endocrinol. metab. (Online) ; 66(2): 168-175, Apr. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1374261
ABSTRACT
ABSTRACT

Objective:

CYP21A2 mutation heterozygote carriers seem to have an increased risk of hyperandrogenism. However, the clinical relevance of the heterozygote carrier status and the reliability of hormonal testing in discriminating a carrier from a non-carrier are puzzling questions. We aimed to characterize a population of Portuguese females suspected of having non-classic congenital adrenal hyperplasia (NC-CAH) due to clinical and biochemical criteria and who have undergone CYP21A2 molecular analysis. Subjects and

methods:

Retrospectively, we have analyzed the clinical records of 131 females (32 girls aged 3-9 and 99 adolescents and premenopausal women aged 13-49) who underwent complete CYP21A2 molecular analysis due to suspicion of NC-CAH. We divided included participants into three groups according to the CYP21A2 molecular

analysis:

NC-CAH females (46), heterozygous carriers (49), and wild type (36). We then compared clinical signs and symptoms as well as biochemical and molecular data between carriers and NC-CAH individuals and between carriers and wild type females. We measured 17OHP by electrochemiluminescence immunoassay.

Results:

Clinical features were similar between groups. Heterozygous carriers presented higher basal and post-cosyntropin 17-hydroxyprogesterone (17OHP) than wild type individuals (p < 0.05) and lower basal and stimulated 17OHP levels than NC-CAH patients (p < 0.05). We discovered a considerable overlap between 17OHP levels among groups. The most common pathogenic variant we identified was p.Val282Leu.

Conclusion:

In this population of hyperandrogenic women and children, heterozygous carriers showed higher basal and stimulated 17OHP than non-carriers although normal basal and stimulated 17OHP responses do not exclude heterozygosity for CYP21A2 pathogenic variants. In this study, only the molecular analysis presented good sensitivity in identifying heterozygotes.


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2022 Type: Article Affiliation country: Portugal Institution/Affiliation country: Universidade do Porto/PT

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2022 Type: Article Affiliation country: Portugal Institution/Affiliation country: Universidade do Porto/PT